Cite
Capeding MR, Sil A, Tadesse BT, et al. Safety and immunogenicity of Vi-DT conjugate vaccine among 6-23-month-old children: Phase II, randomized, dose-scheduling, observer-blind Study. EClinicalMedicine. 2020;27:100540doi: 10.1016/j.eclinm.2020.100540.
Capeding, M. R., Sil, A., Tadesse, B. T., Saluja, T., Teshome, S., Alberto, E., Kim, D. R., Park, E. L., Park, J. Y., Yang, J. S., Chinaworapong, S., Park, J., Jo, S. K., Chon, Y., Yang, S. Y., Ryu, J. H., Cheong, I., Shim, K. Y., Lee, Y., Kim, H., Lynch, J. A., Kim, J. H., Excler, J. L., Wartel, T. A., & Sahastrabuddhe, S. (2020). Safety and immunogenicity of Vi-DT conjugate vaccine among 6-23-month-old children: Phase II, randomized, dose-scheduling, observer-blind Study. EClinicalMedicine, 27100540. https://doi.org/10.1016/j.eclinm.2020.100540
Capeding, Maria Rosario, et al. "Safety and immunogenicity of Vi-DT conjugate vaccine among 6-23-month-old children: Phase II, randomized, dose-scheduling, observer-blind Study." EClinicalMedicine vol. 27 (2020): 100540. doi: https://doi.org/10.1016/j.eclinm.2020.100540
Capeding MR, Sil A, Tadesse BT, Saluja T, Teshome S, Alberto E, Kim DR, Park EL, Park JY, Yang JS, Chinaworapong S, Park J, Jo SK, Chon Y, Yang SY, Ryu JH, Cheong I, Shim KY, Lee Y, Kim H, Lynch JA, Kim JH, Excler JL, Wartel TA, Sahastrabuddhe S. Safety and immunogenicity of Vi-DT conjugate vaccine among 6-23-month-old children: Phase II, randomized, dose-scheduling, observer-blind Study. EClinicalMedicine. 2020 Sep 09;27:100540. doi: 10.1016/j.eclinm.2020.100540. eCollection 2020 Oct. PMID: 33150320; PMCID: PMC7599314.
Copy
Download .nbib